• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

Tracy T. Batchelor, MD, MPH

Giovanni Armenise - Harvard Professor of Neurology, Department of Neurology, Harvard Medical School

Executive Director, Stephen E. and Catherine Pappas Center for Neuro-Oncology, Massachusetts General Hospital

Contact Info

Tracy Batchelor
Massachusetts General Hospital
55 Fruit Street
Boston, MA, 02114
Mailstop: Yawkey Center 9E
Phone: 617-724-8770
Fax: 617-724-8769
Email not available


Carolyn Chamberlain
Academic Assistant
Massachusetts General Hospital
55 Fruit Street
Boston, MA, 02114
Phone: 617-643-1938
Fax: 617-643-2591

DF/HCC Program Affiliation

Neuro-Oncology, Co-Leader

DF/HCC Associations

Member, Center Scientific Council

Research Abstract

My work involves 1) the development of experimental trials of novel agents for patients with glioblastoma and primary CNS lymphoma (PCNSL) and 2) the identification of molecular markers of prognosis in patients with malignant glioma. With respect to therapeutic studies, I am the Principal Investigator (PI) of the MGH U01 grant, New Approaches to Brain Tumor Therapy (NABTT). In this role I have served as the PI of several national, multicenter therapeutic trials (CPT-11 for recurrent glioblastoma; oxaliplatin for newly diagnosed glioblastoma; Methotrexate for newly diagnosed PCNSL; Methotrexate and thio-TEPA for newly diagnosed PCNSL; rituximab for relapsed PCNSL). I am also the PI of an R21-funded study of AZD2171, an oral VEGFR2 tyrosine kinase inhibitor, in patients with recurrent glioblastoma. The study includes correlative investigations of possible drug effects on circulating endothelial and progenitor cells; circulating cytokines and such magnetic resonance imaging (MRI) parameters as arterial spin labeling; perfusion-weighted imaging and diffusion-weighted imaging. Other approved and funded studies of molecularly-targeted drugs in glioblastoma that I lead include: MLN518; PTK787; ZD6474 and sunitinib.

My work on molecular markers of prognosis incorporates data from two major resources: a longitudinal, electronic patient research database and a large brain tumor bank. In our studies we have demonstrated that the prognostic effects of EGFR and TP53 in glioblastoma (survival, response to radiation) are a function of the age of the patient. We have also demonstrated that BCL-6 is a significant positive prognostic marker in patients with PCNSL. Current molecular prognosis studies focus on anaplastic oligoastrocytomas; anaplastic oligodendrogliomas and glioblastoma.


View All Publications